White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
O T WiebengaMenno Michiel SchoonheimHanneke Euphemia HulstG J A NagtegaalEva M M StrijbisMartijn D SteenwijkC H PolmanPetra J W PouwelsFrederik BarkhofJeroen J G GeurtsPublished in: AJNR. American journal of neuroradiology (2016)
In patients with relapsing-remitting multiple sclerosis starting natalizumab treatment, the extent and severity of white matter damage were reduced significantly in the first year of treatment. These findings may aid in explaining the large observed clinical effect of natalizumab in relapsing-remitting multiple sclerosis.